Neurocrine Biosciences Inc at Wells Fargo Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Mohit Bansal - Wells Fargo - Analyst : Great. So maybe I'll hand it over to you, Kyle, because they are like, again, you are filling in big shoes of a great man. So how do you -- I mean, like just talk a little bit about what are you excited about the company? And then what is -- how do you see the company in the next couple of years?

Question: Mohit Bansal - Wells Fargo - Analyst : Great. No, I mean there are a lot of layers to go through here. But one thing I do want to ask you about because you -- I mean, as of now, you are donning the hat of Business Development Officer. And companies in your position where you have had success with first asset and then you are looking for something because that's where we can lock up four years [Nikin] was at. Often, people look for easy route of BD or buy something big and then trying to fill a hole. You actually did not take that route. You tried some early-stage deals, but you went for internal pipeline and working something in-house plus licensing deals. So just walk us through that thought process there because it is like -- I think you did not go for easy or quick fix there. So how did you think about internally about that? And how do you think about ROI and those kinds of stuff on that? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 05, 2024 / 12:45PM, NBIX.OQ - Neurocrine Biosciences Inc at Wells Fargo Healthcare Conference

Question: Mohit Bansal - Wells Fargo - Analyst : Got it. No, that's fair. Super helpful. Let's just dive deeper into some of the assets. So of course, [Muscronicare] have started, expecting it to be --

Question: Mohit Bansal - Wells Fargo - Analyst : So let's just talk about [Muscranic]. You have had some data. I mean street seems a little bit mixed on that data at this point. But let's just put the data in context what you wanted to see versus what you saw there? And how do you think about the data at this point?

Question: Mohit Bansal - Wells Fargo - Analyst : Awesome. So I mean, one question we get a lot and I think -- I mean, you can take it positive and negative in terms of tolerability profile, it looks pretty interesting and clean. But at the same time, there's no dose response as well from like any safety events are not dose related either. How do you read that? I mean, like is it normal in your side that you do not see a dose response on tolerability either?

Question: Mohit Bansal - Wells Fargo - Analyst : Got it.

Question: Mohit Bansal - Wells Fargo - Analyst : Got it. So I mean, of course, like we saw a couple of major deals. So obviously, [Bistrot] bought [Karuna] and then [AbbVie] bought [seller]. And they both talked about -- more so AbbVie about longer acting. So I mean granted right now, you are probably a few years behind the leaders. But given yours is among daily formulation, a single drug versus what [Kona's] doing, is that something with the longer-acting or injectable kind of formulation you can actually bridge that gap?

Question: Mohit Bansal - Wells Fargo - Analyst : Got it. And then maybe -- so it basically [hurt us] for the course kind of approach is fair, like different indications and different molecules. Would that be the case? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 05, 2024 / 12:45PM, NBIX.OQ - Neurocrine Biosciences Inc at Wells Fargo Healthcare Conference

Question: Mohit Bansal - Wells Fargo - Analyst : That's what we found in our work as well, like all the previous orthostatic approaches, safety was the biggest challenge on the efficacy side. [Don] went on as far as there. So let's move on from [Astronics]. So I want to talk a little bit about your DAAO inhibitor, because I think we're expecting data this quarter. So this is more of a cognition mechanism at this point. So talk to us about, I mean, how do you think about the riskiness of this drug at this point? And what have you seen so far, which gives you confidence that we could see something interesting here?

Question: Mohit Bansal - Wells Fargo - Analyst : Are you reaching the trial with patients who have positive impairment?

Question: Mohit Bansal - Wells Fargo - Analyst : Got it. Very helpful. Last two topics I want to touch, [Greenspoint], your smallest product in [Gaza] as well. So let's just talk a little bit about [conesefont] and your prelaunch activities. I mean as you're getting ready there?

Question: Mohit Bansal - Wells Fargo - Analyst : Yes, we have done a survey, a shameless plug. If you want to look at that, sir way. So let's just talk about [INGREZZA] as well. Thank you for this, Matt. So I mean --

Question: Mohit Bansal - Wells Fargo - Analyst : Awesome.

Question: Mohit Bansal - Wells Fargo - Analyst : No, I followed the company since it was expected to be a $500 million track.

Question: Mohit Bansal - Wells Fargo - Analyst : One last question to you, Kyle. Fast forward one year, September 2025. I hope you are coming here. I'll be here. If I ask you the caution, like what would make you look back at the year and say it was a great year for us?

Question: Mohit Bansal - Wells Fargo - Analyst : Thank you.